Metabolism and transport of oxazaphosphorines and the clinical implications. - Wikidata - wikimedia - TriplyDB

Metabolism and transport of oxazaphosphorines and the clinical implications.

Metabolism and transport of oxazaphosphorines and the clinical implications.

http://www.wikidata.org/entity/Q36360811

about

Inorganic nanolayers: structure, preparation, and biomedical applications Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use Insights into CYP2B6-mediated drug-drug interactions Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients A New Method to Quantify Ifosfamide Blood Levels Using Dried Blood Spots and UPLC-MS/MS in Paediatric Patients with Embryonic Solid Tumours Preliminary Safety Assessment of New Azinesulfonamide Analogs of Aripiprazole using Prokaryotic Models Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy Usefulness of the MRP2 promoter to overcome the chemoresistance of gastrointestinal and liver tumors by enhancing the expression of the drug transporter OATP1B1 PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4).A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis.Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics.SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis.The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus Enantioselective liquid chromatography-mass spectrometry assay for the determination of ifosfamide and identification of the N-dechloroethylated metabolites of ifosfamide in human plasma.Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis A molecular model of the enantioselective liquid chromatographic separation of (R,S)-ifosfamide and its N-dechloroethylated metabolites on a teicoplanin aglycon chiral stationary phase.The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies The role of constitutive androstane receptor in oxazaphosphorine-mediated induction of drug-metabolizing enzymes in human hepatocytes.Targeting the metabolic microenvironment of tumors.Urological implications of cyclophosphamide and ifosfamide.Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy?Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.Impact of glomerular kidney diseases on the clearance of drugs.Antimutagenic compounds and their possible mechanisms of action.The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.Molecular mechanisms for tumor resistance to chemotherapy.The Role of Transporters in the Toxicity of Chemotherapeutic Drugs: Focus on Transporters for Organic Cations.The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy.The effect of N-acetylcysteine on the antitumor activity of ifosfamide.Investigation of ifosfamide nephrotoxicity induced in a liver-kidney co-culture biochip.Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.Comparision of uroprotective activity of reduced glutathione with mesna in ifosfamide induced hemorrhagic cystitis in rats.In vitro metabolic fate of alizapride: evidence for the formation of reactive metabolites based on liquid chromatography-tandem mass spectrometry.Impact of severe hypothyroidism on cyclophosphamide disposition and routes of metabolism and transport in a patient with treatment-resistant lupus nephritis.Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis.The protective effects of Cichorium glandulosum seed and cynarin against cyclophosphamide and its metabolite acrolein-induced hepatotoxicity in vivo and in vitro.

P2860

Q26781178-3088A704-9D3F-4617-86D1-863CBBAE0A73 Q28068930-D6DE2893-E60C-4FDB-A0FD-08095560068E Q28078857-B769A6CE-63B9-450A-AED1-8450C21742D2 Q28255901-E02FDFD9-65F1-4784-9FFC-80B814498E57 Q28551109-EFF2CCEF-96C3-4B1E-B7FD-2AE7621EF6FB Q28821520-84844F36-193D-435E-9B95-025F6A4E67A3 Q33344524-24CD83FB-CF86-44B4-9FE1-A62BB76664BB Q33798494-5DA2A964-9A54-4DA2-88BB-35F2B436178D Q33855506-DD4CB238-44F5-4C1F-AD81-B0079AE2062E Q33954656-5416610A-11FE-4C3A-B795-979823F149F4 Q34010773-B05A2276-343C-4695-8C19-023D2B3607BB Q34139167-6FCF2505-C112-4691-87D8-D83DD3726655 Q34307873-2FBBD3F1-1504-48DE-83C8-9F78B8D8343D Q34357861-4725AF78-5105-441C-9710-A454132A7CE7 Q34797388-9CB04FD2-8885-4571-AEFA-246A1C120918 Q35827846-9EC5B687-D1C1-4BC3-870A-0F3FFDDFC4E0 Q36154879-985E4C41-0ABB-4AA5-811B-3DDE8388B02F Q36336024-C9E86419-E63B-447C-B9E8-200E829D757C Q36442512-F4677BAA-96B0-483C-BE7E-4E9B0773213D Q36529490-6420E829-A959-40C9-A6E1-649CEF9211BB Q36988710-34B1E5F0-438F-4B67-9BEE-0E397ED62F41 Q37229190-5600A5B3-D66B-45A2-BA19-F2C55F4D2E74 Q37264407-CBE4AA8F-9C5F-4BAC-B0B9-8C63FA94555C Q37310699-FBF63F92-72A6-44C7-A92D-B646E986D923 Q37386327-9E48D35D-A5BA-4465-8332-D3C316C4A39B Q37974647-36739608-AA09-4F1C-B5D9-088A1572CEDC Q38194959-C2051001-9F11-43B8-BF3A-BA8ACDB232FD Q38291073-4A8AE34E-3414-401A-86DB-A66118B0AD75 Q38813053-07E8B605-45E2-4574-A194-73C66ADD52F9 Q38888345-53B3CE64-0D19-4DB1-AFB2-A7A5B8C71FD1 Q38959130-4C0CBD56-F310-4345-A965-55AC44C96E29 Q39537262-D2BE8EEF-3477-4018-90FF-1317B81BD899 Q39570346-D5E89DBF-5276-4811-AE99-BD9E004595E1 Q39703345-2E38F80E-4864-4383-A134-3DFD96A865F5 Q41677104-6541FF9E-906F-4875-9519-9C818219AF3D Q41851251-EB95AAF5-72A0-474E-A47D-4D64B933ABDC Q42653952-2DB31E9D-DF16-46AF-888F-9D71CC0896B6 Q45084231-2495C4E5-A26A-49F7-9198-09768F224017 Q45958144-6ADE844A-31C3-4762-BB4A-F6057A9C7665 Q46446299-206AD083-1F13-4F02-8691-16F62853E31F

P2860

Metabolism and transport of oxazaphosphorines and the clinical implications.

http://www.wikidata.org/entity/Q36360811

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Metabolism and transport of oxazaphosphorines and the clinical implications.

@ast

Metabolism and transport of oxazaphosphorines and the clinical implications.

@en

type

label

Metabolism and transport of oxazaphosphorines and the clinical implications.

@ast

Metabolism and transport of oxazaphosphorines and the clinical implications.

@en

prefLabel

Metabolism and transport of oxazaphosphorines and the clinical implications.

@ast

Metabolism and transport of oxazaphosphorines and the clinical implications.

@en

P1433

Q36360811-18056DFE-0061-4958-85DB-BD77FA23A872

P1476

Q36360811-65EF6A50-AD50-4491-B1EB-9FB3549E07F0

P2093

Q36360811-04D12E51-6C1D-4E94-993A-332384BE92C2

Q36360811-20CB3AF1-22BC-4967-8A68-A001ED5BB695

Q36360811-2483B9C9-9EC7-48D8-A232-ECFCAD865442

Q36360811-735A278F-9B1D-46FD-B1CD-A9B31EB95541

Q36360811-A13B47C9-5821-4E4F-93B9-1BE0C4FC9F62

Q36360811-B6E7B9F8-385F-4872-BB2F-3F88D27DF1E4

Q36360811-F7FEE7C5-152B-4CBE-A20A-A1D099BB7124

P2860

Q36360811-00A64DFD-3118-4A8C-A6ED-C99F0AB4B32C

Q36360811-010F22A9-6529-407C-8357-99BBAC4EBA48

Q36360811-013F05B6-6F2E-4F68-A124-2E3AAC1392A1

Q36360811-0189F18A-126E-4025-86F6-36AB7B44AA04

Q36360811-03177551-8AFA-4A6E-9554-F60F97D448FF

Q36360811-035AF950-6358-4750-923D-831457D43110

Q36360811-037388F8-610E-4922-A7F5-25AA69522240

Q36360811-03F5807C-0BAA-4795-90C1-7552288A5A76

Q36360811-03F9770C-3468-4E29-B0E8-E54EE902294C

Q36360811-0505C319-D28A-4ACF-8440-B66A6553CEBE

P304

Q36360811-B5B793E6-CA43-48E8-AE2A-3DD50848E380

P31

Q36360811-DEDD2A5C-8DC6-4FE0-BB1C-0401C8E78C2A

P356

Q36360811-8D52399B-9BBC-4CDB-A2EB-6D9C3BA5FAEF

P407

Q36360811-E2B4AFBB-8D5A-48BB-8229-895F1E587358

P433

Q36360811-1F95D8CA-973E-4E82-A6E8-50ADF6B3E9D0

P478

Q36360811-9A560B5E-A178-4378-8291-9AE36246AC5A

P577

Q36360811-E904AC07-D867-4F41-9CBD-CB03A0D9341C

P698

Q36360811-984FC9C5-ED70-4BFE-8AD4-DAA1A34CDBD3

P356

03602530500364023

P1433

Drug Metabolism Reviews

P1476

Metabolism and transport of oxazaphosphorines and the clinical implications.

@en

P2093

Jing Zhang

http://www.w3.org/2001/XMLSchema#string

Quan Tian

http://www.w3.org/2001/XMLSchema#string

Shu Chuen Li

http://www.w3.org/2001/XMLSchema#string

Shufeng Zhou

http://www.w3.org/2001/XMLSchema#string

Sui Yung Chan

http://www.w3.org/2001/XMLSchema#string

Wei Duan

http://www.w3.org/2001/XMLSchema#string

Yi-Zhun Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacogenetics of alcohol metabolism and alcoholism

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

Molecular genetics of human aldehyde dehydrogenase

Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues

Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome

MRP3, an organic anion transporter able to transport anti-cancer drugs

Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1

A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?

The initial clinical trial of nitrogen mustard

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

P304

611-703

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/03602530500364023

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16393888

http://www.w3.org/2001/XMLSchema#string